CORDIS
EU research results

CORDIS

English EN
Novel vaccine vectors to resist pathogen challenge

Novel vaccine vectors to resist pathogen challenge

Objective

Infectious diseases are a major burden and constant threat to European populations and economies. While barely perceived as a danger not too long ago, a combination of potential rapid spread of novel pathogens across the globe, antibiotics resistance, a come-back of “old” pathogens and persistence of yet to be combated pathogens has raised the demand for effective but safe vaccines.
An example of a yet to be combated pathogen is the obligate intracellular bacterium Chlamydia trachomatis. This pathogen is the major cause of sexually transmitted bacterial disease in humans, and poses a world-wide health concern. While responsive to antibiotics, re-infections frequently occur, urging the need for a prophylactic vaccine. Nevertheless, insufficient knowledge on how to vaccinate against intracellular pathogens hampers the development of such vaccines.
In the proposed project, 5 academic and 2 private partners will cooperate to educate early stage researchers (ESR) in the diverse aspects of novel vaccine development. ESR will design and construct innovative and safe virus-, bacterium-, and plasmid-based vaccine vectors that induce both cell-mediated and humoral immunity, to control infections with intracellular pathogens. They will test these vaccines and improve their efficacy in preclinical models of C. trachomatis infection, and unravel the cellular and molecular mechanisms underlying the induction of protective immune responses, to uncover possibilities for general vaccine vector optimisation.
The end-result will be a new generation of safe vaccine vectors that can be exploited to vaccinate against C. trachomatis, and can be adapted to vaccinate against further intracellular pathogens of choice. Moreover, this project will educate a new generation of scientists that, through the offered, integrated training, will be ready to enter the European task force, in academia or industry, to find creative solutions to future pathogen-imposed challenges.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITEIT UTRECHT

Address

Heidelberglaan 8
3584 Cs Utrecht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 531 239,76

Participants (6)

Sort alphabetically

Sort by EU Contribution

Expand all

HEINRICH-HEINE-UNIVERSITAET DUESSELDORF

Germany

EU Contribution

€ 505 576,80

UNIVERSITAT BASEL

Switzerland

EU Contribution

€ 562 553,28

STATENS SERUM INSTITUT

Denmark

EU Contribution

€ 297 522

UNIVERSITA DEGLI STUDI DI SIENA

Italy

EU Contribution

€ 261 499,68

MICROBIOTEC SRL

Italy

EU Contribution

€ 261 499,68

ABERA BIOSCIENCE AB

Sweden

EU Contribution

€ 281 982,96

Partners (1)

Sort alphabetically

Expand all

SCLAVO VACCINES ASSOCIATION

Project information

Grant agreement ID: 812915

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 December 2022

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 2 701 874,16

  • EU contribution

    € 2 701 874,16

Coordinated by:

UNIVERSITEIT UTRECHT

Netherlands